-$0.64 Earnings Per Share Expected for Dicerna Pharmaceuticals Inc (DRNA) This Quarter

Equities analysts expect Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) to announce ($0.64) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Dicerna Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.80) and the highest is ($0.28). Dicerna Pharmaceuticals posted earnings per share of ($0.68) during the same quarter last year, which suggests a positive year over year growth rate of 5.9%. The company is scheduled to issue its next earnings results on Thursday, March 29th.

Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Dicerna Pharmaceuticals.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last posted its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($0.92) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.70) by ($0.22). Dicerna Pharmaceuticals had a negative net margin of 5,895.26% and a negative return on equity of 293.25%. The business had revenue of $0.47 million for the quarter. During the same period last year, the business posted ($0.68) EPS. The company’s quarterly revenue was up 192.6% on a year-over-year basis.

DRNA has been the subject of several research reports. Zacks Investment Research upgraded shares of Dicerna Pharmaceuticals from a “strong sell” rating to a “buy” rating and set a $6.25 price objective for the company in a research report on Monday, October 23rd. HC Wainwright restated a “buy” rating and set a $10.00 price objective (up previously from $6.00) on shares of Dicerna Pharmaceuticals in a research report on Friday, November 3rd. BidaskClub lowered shares of Dicerna Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, January 9th. Chardan Capital restated a “neutral” rating on shares of Dicerna Pharmaceuticals in a research report on Tuesday, January 16th. Finally, ValuEngine upgraded shares of Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, November 2nd. Four equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $8.25.

Dicerna Pharmaceuticals (DRNA) traded down $0.14 during trading hours on Friday, hitting $8.83. 162,162 shares of the stock traded hands, compared to its average volume of 316,233. Dicerna Pharmaceuticals has a one year low of $2.42 and a one year high of $10.24. The company has a market cap of $455.99, a price-to-earnings ratio of -2.57 and a beta of 2.85.

In other news, Director Bain Capital Life Sciences Inv acquired 285,000 shares of Dicerna Pharmaceuticals stock in a transaction on Monday, December 18th. The stock was bought at an average cost of $7.00 per share, with a total value of $1,995,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 29.41% of the stock is currently owned by corporate insiders.

Hedge funds have recently bought and sold shares of the business. Northern Trust Corp lifted its stake in Dicerna Pharmaceuticals by 6.1% during the second quarter. Northern Trust Corp now owns 36,219 shares of the biopharmaceutical company’s stock valued at $114,000 after buying an additional 2,094 shares in the last quarter. Birchview Capital LP lifted its position in shares of Dicerna Pharmaceuticals by 125.0% in the third quarter. Birchview Capital LP now owns 45,000 shares of the biopharmaceutical company’s stock worth $259,000 after purchasing an additional 25,000 shares in the last quarter. Deschutes Portfolio Strategy LLC purchased a new stake in shares of Dicerna Pharmaceuticals in the third quarter worth approximately $575,000. Vanguard Group Inc. lifted its position in shares of Dicerna Pharmaceuticals by 4.5% in the second quarter. Vanguard Group Inc. now owns 340,327 shares of the biopharmaceutical company’s stock worth $1,078,000 after purchasing an additional 14,517 shares in the last quarter. Finally, Palo Alto Investors LLC lifted its position in shares of Dicerna Pharmaceuticals by 4.0% in the second quarter. Palo Alto Investors LLC now owns 500,913 shares of the biopharmaceutical company’s stock worth $1,588,000 after purchasing an additional 19,394 shares in the last quarter. 21.93% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This piece of content was originally published by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another publication, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/01/21/0-64-earnings-per-share-expected-for-dicerna-pharmaceuticals-inc-drna-this-quarter.html.

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

Get a free copy of the Zacks research report on Dicerna Pharmaceuticals (DRNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply